BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16586042)

  • 1. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.
    Miyazaki M; Fujikawa Y; Takita C; Tsumura H
    Clin Rheumatol; 2007 Feb; 26(2):231-9. PubMed ID: 16586042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation.
    Zawawi MS; Dharmapatni AA; Cantley MD; McHugh KP; Haynes DR; Crotti TN
    Biochem Biophys Res Commun; 2012 Oct; 427(2):404-9. PubMed ID: 23000414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
    Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
    J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
    van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
    Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
    Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
    Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression.
    Hounoki H; Sugiyama E; Mohamed SG; Shinoda K; Taki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Miyahara T
    Bone; 2008 Apr; 42(4):765-74. PubMed ID: 18242157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells.
    Hirotani H; Tuohy NA; Woo JT; Stern PH; Clipstone NA
    J Biol Chem; 2004 Apr; 279(14):13984-92. PubMed ID: 14722106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis.
    Yamanaka Y; Abu-Amer W; Foglia D; Otero J; Clohisy JC; Abu-Amer Y
    J Orthop Res; 2008 Dec; 26(12):1577-84. PubMed ID: 18655139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand.
    Shui C; Riggs BL; Khosla S
    Calcif Tissue Int; 2002 Nov; 71(5):437-46. PubMed ID: 12202955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab acts directly on human osteoclast precursors and enhances osteoclast formation induced by receptor activator of nuclear factor kappaB ligand in vitro.
    Takita C; Fujikawa Y; Itonaga I; Taira H; Kawashima M; Torisu T
    Mod Rheumatol; 2005; 15(2):97-103. PubMed ID: 17029043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
    Cheng CP; Sheu MJ; Sytwu HK; Chang DM
    Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation.
    Sharma SM; Bronisz A; Hu R; Patel K; Mansky KC; Sif S; Ostrowski MC
    J Biol Chem; 2007 May; 282(21):15921-9. PubMed ID: 17403683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures.
    Igarashi K; Hirotani H; Woo JT; Stern PH
    Bone; 2004 Jul; 35(1):47-56. PubMed ID: 15207740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menatetrenone (vitamin K2) acts directly on circulating human osteoclast precursors.
    Taira H; Fujikawa Y; Kudo O; Itonaga I; Torisu T
    Calcif Tissue Int; 2003 Jul; 73(1):78-85. PubMed ID: 14506958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.